Mirati Therapeutics, in collaboration with additional groups including Monoceros Biosystems, published a novel Cancer Discovery article entitled “The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Archives

Categories